Allurion Technologies, Inc. (ALUR) Reports Q2 Loss, Misses Revenue Estimates

Company Performance - Allurion Technologies, Inc. reported a quarterly loss of $0.57 per share, which was better than the Zacks Consensus Estimate of a loss of $0.65, representing an earnings surprise of +12.31% [1] - The company posted revenues of $3.38 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 43.21%, and a significant decline from year-ago revenues of $11.77 million [2] - Over the last four quarters, Allurion has surpassed consensus EPS estimates three times but has not beaten consensus revenue estimates [2] Stock Performance - Allurion Technologies' shares have lost about 78% since the beginning of the year, contrasting with the S&P 500's gain of 9.7% [3] - The current Zacks Rank for Allurion is 4 (Sell), indicating expectations for the stock to underperform the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is -$0.54 on revenues of $7.15 million, and for the current fiscal year, it is -$3.14 on revenues of $24.53 million [7] - The outlook for the Medical - Products industry, where Allurion operates, is currently in the top 39% of over 250 Zacks industries, suggesting potential for better performance compared to lower-ranked industries [8]